Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OCGN | US
0.04
4.12%
Healthcare
Biotechnology
30/06/2024
04/10/2024
1.01
0.97
1.03
0.96
Ocugen Inc. a clinical-stage biopharmaceutical company focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400 a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200 a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema diabetic retinopathy and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern Pennsylvania.
View LessLow Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
69.2%1 month
63.5%3 months
71.7%6 months
93.9%-
15.22
17.35
0.41
0.17
-1.95
39.21
-
-50.51M
290.74M
290.74M
-
-1.35K
-
135.30
-114.42
15.03
17.99
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.23
Range1M
0.35
Range3M
1.06
Rel. volume
0.84
Price X volume
3.24M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ADC Therapeutics SA | ADCT | Biotechnology | 3.29 | 318.10M | 8.22% | n/a | -94.48% |
Aldeyra Therapeutics Inc | ALDX | Biotechnology | 5.34 | 317.31M | 0.75% | n/a | 15.90% |
Cerus Corporation | CERS | Biotechnology | 1.7 | 315.00M | 0.59% | n/a | 199.34% |
Immutep Limited | IMMP | Biotechnology | 2.05 | 314.34M | -3.07% | n/a | 0.84% |
Monte Rosa Therapeutics Inc | GLUE | Biotechnology | 5.09 | 312.39M | -5.57% | n/a | 19.74% |
Lyell Immunopharma Inc. Common Stock | LYEL | Biotechnology | 1.22 | 312.32M | -0.81% | n/a | 10.63% |
PEPG | PEPG | Biotechnology | 9.3 | 303.08M | 2.88% | n/a | 12.52% |
Kamada Ltd | KMDA | Biotechnology | 5.2 | 298.89M | -0.57% | 20.04 | 3.41% |
STROUDS INC | STRO | Biotechnology | 3.61 | 295.89M | 2.85% | n/a | 125.14% |
Aviragen Therapeutics Inc | AVIR | Biotechnology | 3.46 | 292.10M | 2.67% | n/a | 0.43% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.95 | 0.76 | Cheaper |
Ent. to Revenue | 39.21 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 17.35 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 71.74 | 74.67 | Par |
Debt to Equity | 0.41 | -1.82 | Expensive |
Debt to Assets | 0.17 | 0.26 | Cheaper |
Market Cap | 290.74M | 3.73B | Emerging |